Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Bellicum Pharmaceuticals)"
Count: 25
Selected: 0
| NCT ID | Title |
|---|
| NCT00868595 | MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer | ||
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors | ||
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | ||
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS | ||
| NCT03639844 | BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study | ||
| NCT03459170 | Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant | ||
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | ||
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | ||
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | ||
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | ||
| NCT02487459 | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | ||
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | ||
| NCT02231710 | Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases | ||
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant | ||
| NCT01823978 | Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer | ||
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | ||
| NCT05620342 | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | ||
| NCT03594162 | Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | ||
| NCT03016377 | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | ||
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | ||
| NCT03696784 | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | ||
| NCT02414269 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | ||
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | ||
| NCT02849886 | T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. | ||
| NCT03721068 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma |
